Medical Device Market Access: The Value Analysis Committee Playbook

2026-08-30 · Caduvo Team

Hospitals don't buy FDA clearances — they buy evidence that a device improves outcomes and doesn't wreck the budget. Here's how the Value Analysis Committee evaluates products and what a realistic MedTech launch sequence actually looks like.

A new device clears FDA, the team celebrates, and then the real silence begins. Hospitals don't return calls. The product sits in a warehouse. You have a clearance, but you don't have medical device market access — and the difference is a Value Analysis Committee.

Market access in MedTech means three things happen in sequence: a payer agrees to cover the procedure, a code exists to bill for it, and the hospital's internal gatekeepers — the Value Analysis Committee (VAC) — approve its use. Miss any one, and the device never reaches a patient.

This post walks through what a VAC actually does, the evidence it demands, and a realistic launch sequencing that respects how these committees operate.

What Medical Device Market Access Actually Means

FDA clearance is a safety and efficacy permission slip. It does not guarantee payment, coverage, or even a shelf in the supply closet. Market access is the operational outcome of three interlocking steps:

1. Coding: You need a billable code — CPT or HCPCS — that describes the product or the procedure it enables. Without one, no hospital can submit a claim. (HCPCS vs CPT codes overview.)
2. Coverage: Payers — Medicare, commercial plans — must issue policies that say they will reimburse for the device or service. An NCD or LCD often sets the tone.
3. Payment rate: Even with coverage, the actual dollar amount must cover the hospital's acquisition cost and leave a margin.

But none of that gets a device onto a hospital formulary. For that, you face the VAC.

Inside the Hospital Value Analysis Committee

A VAC is a standing hospital committee, not a sales call. Its job is to evaluate every new product request through a lens that is clinical, financial, and operational all at once. The committee typically includes:

• Supply chain and materials management (chair)
• Nursing directors from relevant units
• Practicing physicians (often a rotating group)
• Infection control representative
• IT/EHR integration lead if software is involved
• Finance/administration

VACs meet monthly or quarterly. They review a stack of product requests. Your device is one line on a spreadsheet until someone champions it.

The process looks like this:

1. A clinician or department submits a new product request form.
2. The request package goes through a preliminary screening — does a similar product already exist? Is it cheaper?
3. The VAC reviews the clinical evidence, cost impact, and any trial data.
4. They may approve, deny, or ask for a limited trial.
5. If approved, the product is added to the item master, and procurement can order it.

A denial is rarely final. It usually means "come back with better evidence."

The Evidence VACs Actually Ask For

VAC members are overworked. They want a one-page summary and a binder of supporting proof. The evidence they expect falls into four buckets:

Clinical effectiveness

• Peer-reviewed studies, ideally head-to-head comparisons with the current standard of care.
• Registry data or real-world evidence if RCTs are not available.
• Procedure time, length of stay, and complication rate differences.

Economic impact

• A budget impact model that shows net cost or savings per case, per year, for the hospital.
• Not just the device price — include OR time, readmission savings, consumables, and staff time.
• Reimbursement mapping: which CPT codes apply, what Medicare and major commercial payers actually pay for those codes.

Operational fit

• Supply chain requirements (sterilization, storage, shelf life).
• Training burden for nursing and physicians.
• EHR or IT integration steps, if applicable.

Risk and safety

• FDA clearance documentation and any post-market surveillance obligations.
• Infection control data, if relevant.
• Product liability and indemnification stance.

One rule of thumb: if you cannot translate a clinical advantage into a line-item financial impact for the hospital, the VAC may see cost, not value.

Sequencing Your First Launch: A Realistic MedTech Go-to-Market Path

Most teams get the sequence wrong. They start selling before the reimbursement infrastructure is solid, then get blocked by the VAC for lack of an economic story. A workable medical device go to market strategy for a first product looks like this:

1. FDA clearance. For a Class II device, a 510(k) clearance is the baseline. For novel devices, a De Novo or PMA pathway. This must happen first.
2. Secure a payment pathway. Identify the appropriate CPT or HCPCS code. If none exists, plan for a new code application (often a 12-18 month lead time). Confirm that at least one major payer — Medicare if the population aligns — has a coverage pathway. This step often runs in parallel with FDA work.
3. Build the VAC dossier. Package the clinical evidence, the budget impact model, and the reimbursement map into a clean, data-heavy presentation. Include a proposed trial protocol if you plan a limited evaluation.
4. Pilot at 2-3 target hospitals. Choose sites where you have a clinical champion, strong administrative relationships, and a known non-urgent VAC cadence. Use the pilot to collect real-world outcomes and refine the economic model.
5. Scale through VAC approvals. With pilot data, present to additional VACs. A successful trial at one hospital becomes the strongest piece of evidence for the next.

An early mistake is confusing "clearance" with "launch readiness." Until you have a code, a payer policy, and a VAC-approved budget story, the launch is not real.

Key Takeaways

• Medical device market access requires coding, coverage, and hospital committee approval — not one, all three.
• The Value Analysis Committee is a clinical-financial-operational gatekeeper. Treat it like an evidence review panel, not a buyer.
• Evidence needed: clinical data, a hospital-specific budget impact model, and a clear reimbursement map.
• Sequence your medical device go to market strategy as: clearance → coding/coverage → VAC dossier → pilot → scale.
• A single VAC approval, with real-world data, is the most powerful asset for opening subsequent hospitals.
• Tools that surface payer coverage policies and coding pathways can cut weeks out of the evidence-gathering phase. Caduvo, for example, maps the reimbursement landscape so your team walks into the VAC meeting with a complete picture of who pays and how much.